Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 3/20 | 0.46 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.39 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 2/20 | 0.38 |
| ▸ | ACE | P12821 | 6/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247749 | 0.88 | RAMP1 (0.48) | FPR2RAMP1CALCRLACEMME | |
| SCHEMBL5638625 | 0.88 | RAMP1 (0.48) | FPR2RAMP1CALCRLACEMME | |
| SCHEMBL892512 | 0.76 | CHRM5 (0.41) | FPR2CHRM5ADRA2CCCR1ACE | |
| SCHEMBL6986804 | 0.76 | F10 (0.50) | ACE | |
| SCHEMBL6986800 | 0.76 | F10 (0.50) | ACE | |
| SCHEMBL27706684 | 0.75 | RAMP1 (0.43) | FPR2RAMP1CALCRLACEMME | |
| SCHEMBL15578246 | 0.74 | CALCRL (0.41) | FPR2CALCRLACE | |
| SCHEMBL21143944 | 0.74 | ACE (0.44) | ACEMME | |
| SCHEMBL5638958 | 0.74 | ACE (0.44) | ACEMME | |
| SCHEMBL10941726 | 0.74 | ACE (0.59) | ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052599-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | FPR2 1682/4885RAMP1 1668/4885CALCRL 4578/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | FPR2 1992/4885RAMP1 1704/4885CALCRL 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.